Finished product reference
Mebeverine Hydrochloride
Tablet · Oral · 135 mg
- List code
- 787
- Pharmacologic class
- Antispasmodic (direct-acting smooth muscle relaxant)
What it is and how it works
Mebeverine is a musculotropic antispasmodic that acts directly on gastrointestinal smooth muscle, probably by blocking sodium and calcium channels, relieving spasm without affecting normal gut motility. It has no significant systemic antimuscarinic effects.
Indications
Symptomatic relief of irritable bowel syndrome and other conditions with gastrointestinal smooth muscle spasm, such as abdominal pain and cramps.
Dosage and administration (summary)
Adults: 135 mg orally three times daily, preferably 20 minutes before meals; or 200 mg modified-release capsule twice daily.
Contraindications
Paralytic ileus; hypersensitivity to mebeverine.
Warnings and precautions
New or persistent symptoms, particularly in patients over 40 or with alarm features (weight loss, rectal bleeding), should be investigated before treatment. Hypersensitivity reactions such as rash and angioedema are rare. Use with caution in acute porphyria.
Pregnancy
Not recommended in pregnancy because data are limited.
Storage and supply
Store below 25–30 °C.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.